P G Rose1, R Shrigley, G L Wiesner. 1. Division of Gynecologic Oncology, Center for Human Genetics, Department of Genetics, University Hospitals of Cleveland, Western Reserve University, Ohio 44106, USA.
Abstract
OBJECTIVES: Fallopian tube carcinoma is similar to ovarian and peritoneal carcinoma with respect to histology, response to chemotherapy, and prognosis. BRCA germline mutations have been commonly reported in ovarian and peritoneal carcinoma but rarely in other gynecologic cancers. METHODS: A patient with fallopian tube carcinoma and a family history of ovarian carcinoma underwent genetic counseling and BRCA testing as did her daughter. RESULTS: The patient and her daughter were found to have a germline BRCA2 mutation. CONCLUSION: Like a family history of ovarian or peritoneal carcinoma, the occurrence of fallopian tube cancer should alert the clinician to the possibility of an abnormality in the breast cancer susceptibility 1 or 2 genes. Copyright 2000 Academic Press.
OBJECTIVES:Fallopian tube carcinoma is similar to ovarian and peritoneal carcinoma with respect to histology, response to chemotherapy, and prognosis. BRCA germline mutations have been commonly reported in ovarian and peritoneal carcinoma but rarely in other gynecologic cancers. METHODS: A patient with fallopian tube carcinoma and a family history of ovarian carcinoma underwent genetic counseling and BRCA testing as did her daughter. RESULTS: The patient and her daughter were found to have a germline BRCA2 mutation. CONCLUSION: Like a family history of ovarian or peritoneal carcinoma, the occurrence of fallopian tube cancer should alert the clinician to the possibility of an abnormality in the breast cancer susceptibility 1 or 2 genes. Copyright 2000 Academic Press.
Authors: James R Conner; Emily Meserve; Ellen Pizer; Judy Garber; Michael Roh; Nicole Urban; Charles Drescher; Bradley J Quade; Michael Muto; Brooke E Howitt; Mark D Pearlman; Ross S Berkowitz; Neil Horowitz; Christopher P Crum; Colleen Feltmate Journal: Gynecol Oncol Date: 2013-12-12 Impact factor: 5.482
Authors: Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin Journal: Mol Oncol Date: 2009-02-21 Impact factor: 6.603
Authors: R I Olivier; M van Beurden; M A C Lubsen; M A Rookus; T M Mooij; M J van de Vijver; L J van't Veer Journal: Br J Cancer Date: 2004-04-19 Impact factor: 7.640